Customs
analytical
· TaxIntelHub
US Tariffs May Disrupt Indian CDMOs Through Innovator Company Pressure
The U.S. tariffs on patented drugs create uncertainty for Indian CDMOs, despite the current exemption for generics. Monitoring the upcoming review of generic imports is crucial for assessing long-term impacts.
💡 Key Fact
The U.S. imposed tariffs up to 100% on patented pharmaceutical imports, creating uncertainty for Indian CDMOs.
Background
President Trump's move aims to pressure pharma companies to manufacture in the U.S., citing national security and supply chain risks. Generics, comprising 90% of Indian pharma exports to the U.S., are currently exempt.
Source: Business Standard
Explore related case laws, GST sections & more tools
Open TaxIntelHub →